Nervous Disorder TRIZ Cases

Chemical modification of sulfamidase glycans reduces receptor recognition, enabling central nervous system delivery for lysosomal storage disease treatment.

Targeted amino acid mutations in complementarity determining regions improve NGF-binding agent stability and efficacy, resolving sub-optimum pharmacokinetics.

A segmented gamma-hydroxybutyrate formulation rapidly releases half its dose in acidic conditions and the remainder in intestinal buffer.

Non-covalent compounds bind to the SARS-CoV-2 3CLpro catalytic pocket, resolving the trade-off between safety and inhibitory potency.

Dioscoreaceae extract stimulates endogenous nerve growth factor synthesis, resolving safety issues of recombinant proteins while improving therapeutic efficacy.

Selective antibodies recognize neoepitopes on truncated tau proteins, clearing pathological aggregates that current therapies fail to address.

Multispecific binding molecules target nerve growth factor and tumor necrosis factor-alpha receptors to deliver analgesic effects.

An antibody binds to Kallikrein-8 and inhibits its proteolytic activity, reducing anxiety and cognitive impairment in Alzheimer's disease.

Deuterated compounds activate PPARδ to accelerate skeletal muscle regeneration, addressing limited treatment approaches for muscle damage.

Periodic dosing protocol increases monthly migraine day reduction for suboptimal responders without complex differential strategies.

Bifunctional fusion proteins combine OX40 and TRAIL domains to modulate T cell activation.

An oncolytic adenovirus with an E1A alteration and fiber RGD motif targets defective retinoblastoma pathways.

A herbal antidepressant compound preparation combines five specific extracts to deliver effective mood alleviation.

Combining CBD, CBN, and CBG in optimized ratios enhances therapeutic efficacy while minimizing adverse events associated with high single-cannabinoid doses.

Multipotent adult progenitor cells replace lost neurons and restore motor function without triggering immunogenic rejection or ethical concerns.

Lipidated P3 peptides suppress CAG-repeat RNA toxicity by increasing binding affinity and cellular stability.

Administering a monoclonal anti-CGRP antagonist antibody resolves ineffective general management by targeting the specific biological pathway.

Segmented Clostridial neurotoxin injections reduce immune reactions while maintaining migraine prevention efficacy.

An aqueous Alpinia galanga extract improves cognitive performance without the crash associated with caffeine.

Anti-HERV-W envelope protein antibody treats psychotic symptoms by relocating NMDA receptors into synapses.

NIa protease degrades monomeric and oligomeric amyloid beta, addressing the limitation of existing enzymes that fail to clear toxic aggregates.

Detecting specific polypeptides in body fluids enables early brain damage diagnosis.

Oral azelastine hydrochloride addresses side effects from NMDA antagonists by targeting inflammation to slow disease progression.

An infant nutritional composition lowers visceral fat mass by maintaining a linoleic to alpha-linolenic acid ratio between 2 and 7.

GSK3β inhibition compensates for DYRK1A dysfunction, restoring cortical volume and neuronal growth while preserving sociability.

Bipiperdinyl compounds target sigma-1 receptors with high selectivity, enabling precise PET imaging of neurological disorders and cancer.

Local delivery of bioabsorbable carriers reduces inflammation and prevents secondary injury without systemic side effects.

Membrane-activated chelators resolve inadequate treatment effectiveness by selectively disrupting parasite growth through localized ion binding.

Segmented patch structure separates active agent from adhesive to ensure complete dose delivery and reduce side effects.

Specific cannabinoid ratios resolve limited treatment effectiveness by leveraging synergistic CB1 and CB2 receptor interactions.

Site-specific endonuclease activity introduces A673T substitution in the APP gene, impairing BACE1 cleavage and reducing toxic amyloid beta peptides.

Co-expressing interleukin 10 and its receptor type 1 in antigen-presenting cells via viral vectors to establish constitutive autocrine signaling loops.

Surface-bound saccharides on modified AAV vectors enhance central nervous system delivery, reducing invasive procedures and immune interference.

Vinyl polymers stabilize donepezil free base dispersion in oral films, removing sharp taste and reducing formulation weight.

ASTN1-targeting antibodies eliminate inflammatory monocytes before they enter the central nervous system, preventing neurodegenerative disease progression.

Pharmaceutical compositions combine opioid analgesics with antiemetics and stimulants to deliver targeted pain relief.

Liver-directed AAV vectors express neuroproteins to bypass capsid immune responses and establish long-term tolerance in autoimmune disorders.